No Data
No Data
Despite Lower Earnings Than Five Years Ago, Innoviva (NASDAQ:INVA) Investors Are up 25% Since Then
Express News | Innoviva Inc: Innoviva Specialty Therapeutics Anticipates Commercializing Zevtera in Mid-Year 2025
Express News | Innoviva Inc: Under Terms of Agreement, Innoviva, Inc., Will Be Granted Exclusive Marketing Rights to Zevtera in U.S.
Express News | Basilea Pharmaceutica AG Allschwil - to Receive $4 Million Upfront Payment, up to $223 Million in Milestones
Press Release: Basilea Announces Agreement With Innoviva Specialty Therapeutics for the Commercialization of Antibiotic Zevtera(R) (Ceftobiprole) in the United States
Innoviva to Participate in the Citi 2024 Global Healthcare Conference